# S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma

> **NCT00006721** · PHASE3 · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 571 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** rituximab
- **DRUG:** cyclophosphamide
- **DRUG:** doxorubicin
- **DRUG:** prednisone
- **DRUG:** vincristine
- **RADIATION:** tositumomab

## Key facts

- **NCT ID:** NCT00006721
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-03
- **Primary completion:** 2011-09
- **Final completion:** 2025-12
- **Target enrollment:** 571 (ACTUAL)
- **Last updated:** 2026-03-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006721, "S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00006721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*